Secretion of IL-17 by malignant cells isolated from CTCL patients is also dependent on JAK3/STAT3 signaling, and treatment with either a small molecule inhibitor against JAK3 or siRNAs targeting either JAK3 or STAT3 led to abrogation of IL-17 production [79]. Here, JAK3 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.